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Respiratory syncytial virus (RSV) is a leading cause of respiratory disease in infants, young children, immunocompromised
patients, and the institutionalized elderly. Previous work had shown that RNase L, an antiviral enzyme of the interferon
system, could be recruited to cleave RSV genomic RNA by attaching tetrameric 29-59-linked oligoadenylates (2-5A) to an
oligonucleotide complementary to repetitive gene-start sequences within the RSV genome (2-5A antisense). A 29-O-methyl
RNA-modified analog of the lead 2-5A anti-RSV chimera is shown here to have enhanced antiviral activity in cell culture
studies while also cleaving RSV genomic RNA in an RNase L- and sequence-specific manner. When administered intranasally
to RSV-infected African green monkeys, this chimera reduced nasal RSV replication by up to four log10 units in a dose- and
time-dependent manner. © 2002 Elsevier Science
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29,59-oligoadenylates (2-5A) are produced by cells fol-
lowing exposure to interferon and double-stranded RNA
(dsRNA), a common intermediate in viral replicative cy-
cles (Player and Torrence, 1998). The only well-estab-
lished function of 2-5A is activation of a ubiquitous cel-
lular enzyme, ribonuclease L (RNase L), resulting in deg-
radation of single-stranded RNAs (Silverman, 1997).
Although RNase L cleaves RNA nonspecifically, it has
been harnessed to selectively degrade RNA targets by
coupling a 2-5A activator moiety to antisense oligonucle-
otides (Torrence et al., 1993, 1997; Maran et al., 1994;
Silverman et al., 1997). 2-5A antisense compounds asso-
ciate with complementary RNA sequences within cells
and activate latent RNase L to cleave proximal RNA.
Recruitment and activation of RNase L by 2-5A antisense
increases the ability of certain antisense compounds to
cause degradation of the RNA target and thus promises
to increase the impact of antisense drugs on disease. An
important advantage of the 2-5A-antisense strategy is
that 2-5A is bioactive for RNase L when attached to
antisense with advanced chemistries, including peptide
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70nucleic acids and 29-O-methyl antisense (Cramer et al.,
1999; Verheijen et al., 1999).
Respiratory syncytial virus (RSV) is a nonsegmented,
negative-strand RNA virus belonging to the pneumovirus
subfamily of the family Paramyxoviridae (Collins et al.,
1996). RSV is the most common cause of viral bronchi-
olitis and pneumonia in children, infecting infants from 6
weeks to 6 months of age, where it usually causes upper
respiratory infection, but in 10–50% of the cases lower
respiratory symptoms occur (La Via et al., 1992; Wyde,
1998). Outbreaks in the United States frequently reach
epidemic proportions during the winter months, leading
to roughly 500 deaths per year (Shay et al., 2001). Among
viral respiratory infections, RSV accounts for 40–50% of
hospitalizations for bronchiolitis, and 25% for pneumonia
(La Via et al., 1992). RSV is also a major cause of noso-
comial infections, and severe pneumonia can occur in
the elderly (Wyde, 1998). Although pharmacological
agents have been approved for the treatment (Ribavirin)
or prevention (Respigam, Synagis) of RSV infection in
high-risk individuals, the continued prevalence of RSV
outbreaks demonstrates a strong need for effective RSV
therapeutics.
The RSV virion consists of a helical nucleocapsid
within a lipid envelope with a single strand of negative-
sense genomic RNA that is divided into 10 nonoverlap-
ping genes (Collins et al., 1996). Transcription of each
gene begins at the first nucleotide of a highly conserved
signal (consensus 5 39-CCCCGUUUA-59) found at gene-
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nome (Mink et al., 1991; Jairaith et al., 1997; Player et al.,
1998a). Previous cell culture antiviral studies have tar-
geted these sequences with antisense to inhibit RSV
replication (Jairaith et al., 1997; Player et al., 1998a). Thus,
the 2-5A antisense chimera NIH351, containing core se-
quences complementary to the conserved nine-nucle-
otide gene-start sequence, effectively inhibited RSV rep-
lication when administered to cells in a single dose just
prior to, or 1 h following, virus absorption (Player et al.,
1998a).
To provide greater in vivo stability and higher affinity
for target sequences, 29-O-methyl-modified chimeric
2-5A anti-RSV compounds were synthesized. 29-O-methyl
antisense moieties confer enhanced nuclease resis-
tance and exclude any contribution of RNase H (Inoue et
al., 1987; Lesnik and Frier, 1995; Cramer et al., 1999). Our
results provide the first cell-based demonstration of
RNase H-independent cleavage of targeted RNA by a
2-5A antisense chimera and represent the first report in
which 2-5A antisense effectively suppressed RSV repli-
cation in a primate.
RESULTS AND DISCUSSION
Cell-based analysis of a 29-O-methyl-stabilized 2-5A
anti-RSV chimera
T
CPE Reduction Data Using 2-5A A
Chimera Structure/sequence
Chime
descrip
RBI034 spA4-Bu2-(AsAsAsAAUGGGGCAAAsUsAsA)m Lead chimer
NIH351 spA4-Bu2-d(AsAsAsAATGGGGCAAAsTsAsA) DNA version
RBI066 spA4-Bu2-(GsAsUsAGAAAUAGAAsGsCsA)m Scrambled s
RBI065 (AsAsAsAAUGGGGCAAAsUsAsA)m Non-2-5A
RBI064 spA2-Bu2-(AsAsAsAAUGGGGCAAAsUsAsA)m Defective 2-5
RBI062 spA4-Bu2-(AAAAAUGGGGCAAAUAA)m No PS
RBI063 (AAAAAUGGGGCAAAUAA)m No PS, No 2
RBI045 spA4-Bu2-(AAAAAUGGGGCAAAsUsAsA)m 39-only PS
RBI035 spA4-Bu2-(AsAsAsAAUGGGGCsAsAsA)m Shortened a
Note. Oligonucleotides were added to cells 1 h after exposure to vir
5, before all of the cells in the virus-infected untreated control wells exh
subscripted m represent 29-O-methyl-modified chimeras. A lowercase
nucleotides represent mismatched bases.
a Representative EC50 values (in mM) are the concentration of oligonu
mM) are the concentration of oligonucleotide that reduced uninfected
a single, representative experiment.
b Average relative activity of each chimera compared to RBI034; bas
of each compound was calculated as follows: The EC50 was determine
1 and the activities of other chimeras relative to RBI034 were transform
EC50 of second chimera was twice that of RBI034). Relative activities f
standard deviation (SD) calculated.
c Paired Student’s t test, two-tailed, versus RBI034.To improve the stability of the 2-5A anti-RSV chimera
NIH351 (Player et al., 1998a), a 29-O-methyl-modified ver-sion of the oligonucleotide was synthesized (Irribarren et
al., 1990; Cramer et al., 1999). The resulting second-
generation chimera, RBI034, included the same 39- and
59-terminal internucleotide phosphorothioate (PS) link-
ages for enhanced exonuclease resistance, and a 59-
thiophosphate modification to prevent phosphatidic
cleavage of the critical 59-monophosphate residue (Xiao
et al., 1998). When applied to cells daily for 3 days
(starting 1 h after infection), RBI034 was ;50% more
effective than NIH351 in preventing RSV replication as
determined by using a cytopathic effects (CPE)-reduction
assay (Table 1) or virus yield reduction assay (Table 2).
Similar results were obtained when cells received only
one or two treatments over the same time frame (Table
3). RBI034 was not cytotoxic at doses up to 50 mM, the
highest dose tested (Table 1). Sequence specificity was
confirmed by using a sequence-scrambled control chi-
mera, RBI066, which had EC50s greater than 3.3 mM
(Tables 1–4). RNase L activation was required for full
activity as demonstrated by several compounds, notably
RBI065, which had an antisense moiety identical to
RBI034 but lacked the 2-5A attachment. RBI034 was
seven- to eightfold more active than RBI065, regardless
of treatment protocol (Tables 1–3). Similar results were
obtained with RBI064, which had a fully complementary
antisense portion, but only a dimeric 2-5A attachment
that was incapable of activating RNase L (Table 1).
se Chimeras—Three Treatments
Representativea
EC50
Representativea
IC50
Relativeb
activity
(Mean 6 SD)
Significancec
level
0.10 .50 1
0.26 .10 1.5 6 0.8 P , 0.6
e .3.3 .10 .23 P , 0.0001
0.75 .10 7.5 6 2.8 P , 0.01
0.9 .10 7.5 6 2.5 P , 0.01
0.36 .10 3.7 6 1.3 P , 0.1
.3.3 .10 .23 P , 0.001
0.38 .10 4.7 6 2.5 P , 0.1
e 0.17 .10 1.4 6 0.2 P , 0.6
again 25 and 49 h postinfection. The assay was stopped on day 4 or
igns of virus cytopathicity. Antisense moieties followed by a lowercase,
eding the antisense moiety designates deoxyribonucleotides. Bolded
e that reduced virus replication by 50%. Representative IC50 values (in
nolayer density by 50%. The EC50 and IC50 values presented are from
the results of four independent experiments (n 5 4). Relative activity
ach chimera. The EC50 value obtained for RBI034 was arbitrarily set at
a ratio between the two (e.g., a relative activity of 2 indicates that the
chimera were averaged from four independent experiments and theABLE 1
ntisen
ra
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ntisens
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d for e
ed to
or eachRBI034 added to cells 3 h postinfection inhibited viral
replication as effectively as when added 1 h postinfec-
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threefold less active (data not shown).
To assess the contributions of oligonucleotide length
and stabilizing PS linkages on chimera biological activity,
a series of modified chimeras were tested in CPE reduc-
tion studies. RBI035 was shortened by the three 39-
terminal nucleotides, but had roughly the same activity
as the longer RBI034 (Table 1). When either the 59-
proximal PS linkages alone (RBI045) or all of the PS
linkages (RBI062) were removed, the resulting com-
pounds had less antiviral activity (4.8- and 3.8-fold, re-
spectively) but were still more active than similar non-
2-5A controls (compare to RBI063, Table 1). The slightly
reduced activity of RBI045 and RBI062 as compared to
RBI034 may result from increased sensitivity to intracel-
lular nucleases.
None of the compounds tested were cytotoxic within
the effective dose ranges. All chimeras had IC50s (the
concentration required to reduce cell viability by 50%)
greater than 10 mM (the highest dose tested for most—
Table 1). The IC50 for RBI034 was greater than 50 mM.
Together these results indicated that RBI034 was a
highly effective, nontoxic anti-RSV compound that exhib-
ited both sequence- and 2-5A-specific effects.
TABLE 2
Virus Yield Reduction Data Using 2-5A Antisense Chimeras
Oligonucleotide
Average
EC50
a (mM)
Relativeb
activity (6SD)
Significancec
level
RBI034 0.03 1
NIH351 0.04 1.6 6 0.8 P , 0.4
RBI066 .3.3 .156 P , 0.0001
RBI065 0.28 8.7 6 4.3 P , 0.04
Note. Oligonucleotides were added to cells 1 h following virus
exposure.
a Average EC50: concentration of oligonucleotide (mM) that reduced
virus replication by 50%. Average of four independent experiments.
b Relative activity indicates the average activity (6SD) relative to
RBI034 for each compound.
c Paired Student’s t test, two tailed, versus RBI034.
T
CPE Reduction Data Using 2-5A A
Oligo Coadmin., 1 trt t test 1 h p
RBI034 0.03 (7) 0.
NIH351 0.14 (5) P , 0.2 0.
RBI066 .3.3 (5) P , 0.001 .3
RBI065 0.25 (7) P , 0.001 1
Note. The indicated oligonucleotides were added to cells either with
(2 trt). Four or five days later the cells were stained, syncytia were cou
under Materials and Methods. Numbers in parentheses indicate the number o
two-tailed, determined the level of significance versus RBI034.Cleavage of RSV genomic RNA
To assess the effects of 2-5A anti-RSV compounds
on the targeted RSV genomic RNA, reverse transcrip-
tase coupled polymerase chain reaction (RT-PCR) was
used to amplify two of the more highly conserved
RBI034 target regions within the genome, the NS1/NS2
gene start site and the NS2/N gene start site (Fig. 1A).
The primer used to reverse transcribe the genomic
RNA was 39 of the leader/NS1 start site, which con-
tains another canonical target sequence. Thus, cleav-
age in this region would reduce further the amount of
cDNA template available for subsequent PCR amplifi-
cations. These primer sets could not amplify RSV mR-
NAs since the RT primer was specific to the genome
and because the PCR primer sets were located in
different transcripts. Treatment of cells with 500 nM
NIH351 or RBI034 led to a significant (.90%) decrease
in the RNA representing the assessed subgenomic
regions. The control compound RBI066 had no effect
and RBI065 had intermediate effects (Fig. 1B). The
modest reduction (;30%) in RSV genomic RNA by
RBI065 could result from inhibition of replication rather
than RNA decay. To control for nonspecific cleavage of
cellular transcripts, glyceraldehyde-3-phosphate dehy-
e—Various Treatment Regimens
rage EC50 (n)
t t test 1 h p.i., 2 trt t test
0.21 (4)
P , 0.2 0.35 (4) P , 0.4
P , 0.0001 .3.3 (3) P , 0.0001
P , 0.2 1.59 (3) P , 0.2
oadministration), 1 h postinfection (p.i.), or 1 h p.i. and again 24 h later
nd the EC50 (mM) was calculated by regression analysis as described
TABLE 4
2-5A Antisense Activity against Different RSV
Subtypes—EC50s (mM)
Oligonucleotide
Virus strain/type (HEp-2 cells)
9320/A 393/B CH18537/B
RBI034 0.2 0.75 0.5
RBI066 5.0 .7.5 7.5
Note. Oligonucleotides were added to cells immediately following
virus exposure. EC50 values are the concentration of oligonucleotide
(mM) required to reduce virus replication by 50%, and the values
presented are from a single experiment. RSV A2, CH18537 (B), and
9320 (A) were acquired from ATCC. Strain 393 (B) was acquired from
Richard Weltzin (Oravax, Inc.; Cambridge, MA).ABLE 3
ntisens
Ave
.i., 1 tr
22 (5)
34 (4)
.3 (5)
.1 (5)
virus (c
nted, af independent experiments for each compound. Paired Student’s t test,
primer
the sam
732-5A ANTISENSE TARGETING RSVdrogenase (GAPDH; Fig. 1B) and double-stranded RNA-
dependent protein kinase (PKR) (data not shown) mRNA
levels were examined by RT-PCR and found to be unaf-
fected by treatment with any of the chimeras tested.
Antiviral specificity and activity in monkey cells
RBI034 was effective against both A and B subtypes of
RSV, although it was slightly more potent in inhibiting A
strains (Table 4), confirming that RBI034 has broad spec-
FIG. 1. RT-PCR analysis of RSV genomic RNA fragments following tre
of the negative-stranded RSV genome showing the organization of ge
genomic RNA into cDNA (primer 19) and for PCR amplifying specific s
above the schematized genome (which is presented in a 39-to-59
conserved with the RBI034 oligomer. Locations within the genom
described in Player et al. (1998a). (B) RT-PCR amplification of RSV
infected with RSV at an m.o.i. 5 0.1 (lanes 2–12). Infected cells we
anti-RSV chimeras within 5 min of infection (lanes 5–12). Total ce
separated on a 1% agarose gel, transferred to nylon membrane, and
panel) probes. The top panel represents PCR products amplified by
primers 22 and 53. GAPDH was RT-PCR amplified separately fromificity against different RSV strains. When tested against
another paramyxovirus family member, human parainflu-enza virus-3 (HPIV3), RBI034 had no effect on replication
(data not shown). This was consistent with the absence
of the target sequence for RBI034 in HPIV3. It was critical
to evaluate the activity of RBI034 in African green mon-
key cells in preparation for subsequent in vivo antiviral
testing since the 2-5A structural elements required for
optimal RNase L activation varies among mammals
(Krause et al., 1986). RBI034 inhibited RSV replication in
African green monkey MA104 cells at concentrations
t of infected cells with 2-5A anti-RSV chimeras. (A) Schematic diagram
e relative locations of specific primers used to reverse transcribe the
omic fragments (primers 3, 21, 22, and 53) are shown. Vertical arrows
tion) represent putative intergenic target sequences most highly
dditional, less highly conserved intergenic target sequences are
omic fragments. Cells were either left uninfected (lane 1) or were
n left untreated (lanes 2–4) or were treated in duplicate with 2-5A
NA was isolated 18 h later. RT-PCR amplification products were
ized with RSV-specific (top two panels) or GAPDH-specific (bottom
s 3 and 21, and the middle panel represents products obtained with
e RNA.atmen
nes. Th
ubgen
orienta
e of a
subgen
re the
llular R
hybridcomparable to those observed in human cells (Table 5;
compare to results in Table 1).
74 LEAMAN ET AL.Antiviral activity in an African green monkey model
The cell culture based studies were extended to an in
vivo model of RSV replication in African green monkeys.
RBI034 was delivered at varying doses (0.1–50 mg/kg) by
nasal instillation to groups of two to three animals 30 min
after intranasal administration of about 106 TCID50 of
RSV-A2 strain and twice daily thereafter for five addi-
tional days (Weltzin et al., 1996). Beginning on day 1
postinfection, nasal swabs were taken each morning
prior to the first chimera administration. A single swab of
both nostrils was placed in 1 ml of medium, which was
applied in half-log10 dilutions (from 10
21 to 1027) to HEp-2
indicator cells for CPE analyses. Titers are expressed as
the greatest dilution showing viral cytopathology. The
two highest doses tested, 10 and 50 mg/kg, provided
significant reduction in nasal viral titers over the treat-
ment period (Fig. 2A). The lowest doses (0.1 and 1.0
mg/kg) had no significant effect on virus shedding, al-
though they did delay the onset of virus detection by
about 1 day (data not shown). The antiviral effects were
dose-dependent, and at the 50 mg/kg body weight dose,
viral titers were ;10,000-fold lower than observed in
saline-treated animals on day 6 p.i. (Fig. 2B). Only after
oligonucleotide administration ended (on day 5, see ar-
row) did viral titers rise in the animals receiving the
higher doses, and they did not reach the maximal titers
observed earlier in the untreated animals (Fig. 2A).
The results presented here provide the first cell- and
animal-based demonstrations that 2-5A antisense chi-
meras can elicit RNase H-independent effects, and the
first evidence that an oligonucleotide therapeutic agent
can effectively suppress RSV replication in a primate.
The development of antisense strategies that do not rely
on RNase H activation, such as the 2-5A antisense ap-
proach, may provide a means to utilize advanced base
chemistries that afford higher affinity, greater in vivo
stability, and thus specific and longer acting drugs (Nyce
and Metzger, 1997; Player et al., 1998b). Moreover, the
linkage of 2-5A enhances the efficacy of antisense, pre-
sumably by harnessing the action of RNase L. Future
TABLE 5
2-5A Antisense Activity in African Green
Monkey Cells—EC50s (mM)
MA-104 cells (RSV A2)
RBI034 0.04 6 0.002
RBI066 .3.3
RBI065 0.38 6 0.13
Note. Oligonucleotides were added to cells immediately following
virus exposure. EC50 values are the concentration of oligonucleotide
(mM) required to reduce virus replication by 50%, and the values
presented are from three independent experiments (6SD).studies are required to address issues of delivery to the
lower pulmonary tract where advanced RSV infectionsreside. Aerosolized delivery of oligonucleotides to the
lungs has been performed successfully (Nyce and
Metzger, 1997), and surfactants present in the pulmonary
tract may assist in oligonucleotide uptake into the cells.
Therefore, while the highly potent and minimally toxic
profile of 2-5A antisense makes it an attractive experi-
mental therapeutic agent, efforts aimed at directing the
drug to the lower respiratory tract can be expected to
improve further its efficacy for the treatment of RSV.
MATERIALS AND METHODS
2-5A antigenome chimera synthesis
Chimeric oligodeoxyribonucleotides were synthesized
by using solid-phase phosphoramidite chemistry as de-
scribed previously (Xiao et al., 1996; Player et al., 1998b;
Leaman and Cramer, 1999). Chimeric 29-O-methyl oligo-
nucleotides were synthesized and purified analogously
by replacing deoxyphosphoramidites with 29-O-methyl
phosphoramidites. Phosphorothioate linkages were in-
troduced by oxidizing with 0.05 M [3H]1,2-benzodithiol-3-
FIG. 2. Effect of RBI034 on nasal RSV titers in African green monkeys.
(A) Virus titers in the nasal passages of African green monkeys left
untreated (0 mg/kg; n 5 3) or treated with 10 mg/kg (n 5 3) or 50 mg/kg
(n 5 1) body weight RBI034 twice daily were analyzed on indicator
HEp-2 cells. Treatment continued for 5 days p.i. (6 days total—see
arrow), and nasal swabs were collected prior to the first daily treatment.
Values represent the dilution at which cell lysis was no longer detect-
able and the y-axis is a log10 scale and reflects the average titer in
swabs of all animals in the treatment group (6SD). (B) Dose depen-
dence of RBI034’s effects. Average viral titers (Log10) in nasal passages
on day 6 p.i. were plotted against treatment dose. Values represent the
average titers obtained in nasal swabs of three animals per group
(6SD) except for the 50 mg/kg group that included only one animal.
752-5A ANTISENSE TARGETING RSVone 1,1-dioxide (Beaucage Reagent) (Glen Research) or
0.025 M 3-ethoxy-1,2,4-dithiazoline-5-one (EDITH) (Per-
septive Biosystems) in acetonitrile. Sulfurization reac-
tions were prolonged from 60 to 300 s for 29-O-methyl
internucleotide phosphorothioate linkages.
The 2-5A antigenome compounds have the general
formula sp59A29(p59A29)3pO(CH2)4OpO(CH2)4O(p59N39)n,
where N is either a deoxy- or 29-O-methyl nucleotide, and
the italicized, subscripted n is the number of bases in the
antisense cassette (binding domain). The 29-O-methyl
compounds are represented as spA4-Bu2-(N)m, where the
subscripted m designates the 29-O-methyl modification.
The 59-terminus of the 2-5A moiety bears a monothio-
phosphoryl group and the antisense cassette is of vary-
ing nucleotide composition and may include limited num-
bers of PS internucleotide linkages (see Table 1).
All 2-5A-anti-RSV chimeras were analyzed by HPLC.
Due to the G-quartet and the high purine content, the
lead compound RBI034 tended to aggregate. Therefore,
a new anion exchange method using a PA-100 (250 3 4
mm) column (Dionex) was developed. A linear gradient
was run from 1 to 95% mobile phase B in A within 60 min,
where A was 6 M urea in acetonitrile/water (30:70, v/v)
and B was 395 mM sodium perchlorate, 6 M urea in
acetonitrile/water (30:70, v/v). A flow rate of 1.5 ml/min
was used. The chimera needed for primate studies was
purchased from Hybridon, Inc. (Milford, MA).
Cytopathic effects reduction assay
CPE reduction assays were performed as described
by Sidwell and Huffman (1971) with slight modifications.
HEp-2 cells (ATCC) were infected with RSV strain A2
(ATCC) at a multiplicity of infection (m.o.i.) 5 0.01, and
each of the test compounds were provided to duplicate
wells at final concentrations ranging from 3.3 to 0.015 mM
using 1/3-log10 stepwise dilutions. For each compound,
two wells were set aside as uninfected, untreated cell
controls and two wells per test compound received virus
only as a control for virus replication. The assay was
stopped after 4–5 days, before all of the cells in the
virus-infected untreated control wells exhibited signs of
virus cytopathology (giant cell formation, syncytia, cell
rounding, etc.). Cells were fixed with methanol (10 min)
and then stained with crystal violet (0.1% w/v, 1 min).
Darkly stained syncytia in each well were counted and
the 50% effective concentration (EC50) was calculated by
using regression analysis, based on the mean numbers
of syncytia at each concentration of compound. Virus
yield reduction assays were performed essentially as
described by Cirino et al. (1997), except that human
HEp-2 cells were used as indicator cells, the starting
viral titer for the experiments was m.o.i. 5 0.01, and the
compounds were added directly following virus infection.
The neutral red uptake assay (Cavenaugh et al., 1990)
was used to assess cytotoxic effects of the test com-pounds on cultured cells using the modifications de-
scribed in Player et al. (1998a), with the exception that
the treatments were carried out for a minimum of 1 week.
RNA analyses
The reverse transcriptase coupled polymerase chain
reaction was used to evaluate the effects of the 2-5A
chimeras on RSV genomic RNA. HEp-2 cells (3 3 105
cells/35 mm2) were infected with RSV (strain A2) at an
m.o.i. 5 0.1 in 1 ml of 2% FCS MEM. Antigenome chime-
ras were added within 5 min. Total cellular RNA was
isolated after 18 h by using Trizol reagent (Life Technol-
ogies). RSV genomic RNA was reverse transcribed from
2 mg of total cellular RNA by using a RSV-specific primer
(primer 19: TGCGTACAACAAACTTGCGT, Fig. 1A) in a 20
ml RT reaction (Promega). RSV subgenomic fragments
were PCR amplified (24 cycles; 94°C, 1 min; 65°C, 1 min;
72°C, 2 min; 25 ml final volume) from 2 ml of the RT
reaction by using primer sets shown in Fig. 1A (primers
3: GGCAGCAATTCATTGAGTATG; 21: TGTTATGATGTCTG-
GTTAG; 22: GTTCTTAGAATGCATTGGC; 53: AGTGTAT-
CATTCAACTTGAC). Under these conditions, no amplifi-
cation products were visible when separated on an
ethidium bromide stained gel. Therefore, 15 ml of each
PCR reaction was separated on 1% agarose gel and
transferred to nylon membrane (Hybond N1, Amersham)
for Southern blot analysis. A RSV genome-specific probe
encompassing the NS1, NS2, and N genes (amplified by
using primers 19 and 53, Fig. 1A) was utilized. The
GAPDH probe encompassed sequences 273-1035 of the
GAPDH transcript (gb:M33197). Gel-purified RSV genomic
cDNA and GAPDH cDNA inserts were labeled by using the
AlkPhos nonradioactive detection kit (Amersham). After hy-
bridization at 50°C overnight, the blots were washed, incu-
bated with the supplied chemiluminescent reagent for 5
min, and then exposed to X ray film (XAR, Kodak).
Animal protocols
All animal protocols were approved by the IACUC at
the Tulane Regional Primate Research Center. Fourteen
African green monkeys from the island of St. Kitts were
quarantined for 6 weeks, during which time they were
bled and tested for the absence of prior antibody to RSV.
On day 0 of the experimental protocol, animals were
weighed and 3 ml of blood was drawn as a baseline
serum sample. While sedated (Ketamine), they were in-
oculated with RSV-A2 strain by instillation of 0.25 ml/
nostril of an inoculum containing 106 TCID50 per ml (Welt-
zin et al., 1996). Thirty minutes after inoculation, the first
dose of freshly prepared RBI034 chimera was adminis-
tered to groups of three monkeys at doses of 0, 0.1, 1.0,
and 10 mg/kg. One group of two monkeys received a
dose of 50 mg/kg. The doses were given in a volume of
0.5 ml by administration of 0.25 ml per nostril. The mon-
keys were placed on their backs for 15 min before re-
76 LEAMAN ET AL.turning to their cages. Treatments were repeated at 12 h
intervals for 6 days (day 0–5). Beginning on day 1 and
continuing through day 12, nasal swabs were taken each
morning (before compound administration on treatment
days). Calcium alginate fiber-tipped swabs on aluminum
wires were used to swab both nostrils and then were
placed in 1 ml of complete medium (5% FCS MEM plus
antibiotics). Half-log10 dilutions of this stock were pre-
pared in 2% FCS MEM and applied to HEp-2 cells plated
48 h earlier on 24-well plates. The plates were incubated
for 7 days when titers were determined by microscopic
examination of the cultures for viral cytopathology. The
titers were expressed as the greatest dilution producing
viral cytopathic effects. Based on previous data (Kakuk et
al., 1993; Weltzin et al., 1996), a reduction of titer of 1.0
log10 or greater reflects an antiviral effect. Blood samples
were drawn on days 14 and 21 postinfection to confirm
the presence of antibodies to RSV using a neutralization
assay. Antibodies to RSV developed in all animals (data
not shown).
With one exception, all monkeys fared well through the
21 day experiment with no signs of toxicity associated
with the treatment. One animal receiving 50 mg/kg of
chimera died as a result of aspiration pneumonia asso-
ciated with intubation problems encountered during the
performance of bronchoalveolar lavage sampling on day
3. Necropsy confirmed the presence of lung hemorrhage
that was determined to be unrelated to the compound
administration. No weight loss or clinical symptoms of
RSV infection were observed in the other animals.
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